Expert Pitch
Washington University in St. Louis

WashU Expert: Trump’s New NAFTA Won’t Lower Domestic Drug Prices

Newswise — President Donald Trump has touted his new United States-Mexico-Canada Agreement (USMCA) as a way to boost the American economy. It may not, however, have any impact on one of his other campaign promises: reducing prescription costs for U.S. consumers, says a drug pricing expert at Washington University in St. Louis.

Buried in the draft of the new pact is a provision that would give pharmaceutical companies a minimum of 10 years to exclusively market biologic drugs, a set of complex medications made from living cells.

The Trump administration claims the USMCA would protect their profits.

“In the U.S., we give innovator pharmaceutical companies some period of exclusivity after their product comes to market, before which a biosimilar drug can be approved on the strength of the innovator drugs application in the first instance,” said Rachel Sachs, associate professor of law in the School of Law and an expert on drug policy and pricing.

“The new USMCA agreement would extend the exclusivity period that we apply in the U.S. to Canada and Mexico. This means that biosimilar drug companies may have to wait longer in those countries to bring their products to market, thus theoretically boosting profits of U.S. drug manufacturers,” Sachs said.

We distinguish biologics from small molecule drugs such as aspirin, which are made through standard chemical synthesis techniques, she said.

“Biologics are much more complex molecules,” Sachs said. “They are more difficult to make, and it’s much harder to make follow-on versions of them. A small molecule follow-on drug is quite easy and cheap to make, but a biosimilar product — so-called because we can’t even show it to be identical to the biologic — often is far more expensive to make.”

What impact does this ultimately have on prices in America?

None at all, Sachs said.

“There is no relationship between rising prices on drugs abroad and lowering prices in the United States,” she said. “The Trump Administration has on occasion tried to draw this link, but it is not correct.

“If the Trump administration thinks that pharmaceutical companies need to be rewarded a certain amount for their products in order for them to keep making more products, and if it would like to lower drug prices in the U.S., it can make sure that companies have sufficient incentive by increasing prices abroad,” Sachs said.

“This is, perhaps, one step of a strategy to lower drug prices in the United States,” she said, “but there is no reason why USMCA as drafted would have an impact on domestic pricing.”

Filters close

Showing results

110 of 5683
Released: 2-Dec-2020 7:15 AM EST
Congress Must Act To Fortify Health Care System And Protect Access To Care
American College of Radiology (ACR)

The final 2021 Medicare Physician Fee Schedule fails to avert the potential impact on seniors of payment cuts to more than a million health care providers already reeling from COVID-19’s financial impact. If Congress does not act now to address these changes, the results may be devastating for patients, communities and providers.

Released: 1-Dec-2020 11:10 AM EST
‘Fairmandering’ data tool makes redistricting more representative
Cornell University

A new mathematical method developed by Cornell University researchers can inject fairness into the fraught process of political redistricting – and proves that it takes more than good intent to create a fair and representative district.

Newswise: Efficient In-person voting observed by URI VOTES research team
Released: 30-Nov-2020 4:30 PM EST
Efficient In-person voting observed by URI VOTES research team
University of Rhode Island

The 2020 election is all but complete, but a team of researchers at the University of Rhode Island is still crunching the numbers – not the number of votes, but the statistics used to determine the efficiency of in-person voting in Rhode Island, Nebraska and Los Angeles.

Newswise: Rutgers Philosophy Professor Analyzes Justice Issues in New Podcast
Released: 30-Nov-2020 9:30 AM EST
Rutgers Philosophy Professor Analyzes Justice Issues in New Podcast
Rutgers University-New Brunswick

Rutgers-New Brunswick philosophy Professor Derrick Darby is helping to bring logic and data to discussions on the struggle for justice in America and globally in A Pod Called Quest.

Released: 20-Nov-2020 4:25 PM EST
Those darn property taxes! Insights from Texas tax protests
University of California, Berkeley Haas School of Business

Everyone loves to complain that their taxes are too high. Yet few people actually take the time to formally protest them. A recent deep-dive into property tax appeals in Texas offers new insights on what motivates people to protest or accept their tax obligations.

Showing results

110 of 5683